Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System

BACKGROUND: Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). OBJECTIVE: To examine the association between use of PCSK9 inhibitors with and without concurrent statins and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Lingqing, Chen, Congqin, Yang, Yongkuan, Fang, Jie, Cao, Longxing, Liu, Yige
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808238/
https://www.ncbi.nlm.nih.gov/pubmed/35140810
http://dx.doi.org/10.1155/2022/9866486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808238/
https://www.ncbi.nlm.nih.gov/pubmed/35140810
http://dx.doi.org/10.1155/2022/9866486

Ejemplares similares